Skip to main content

Advertisement

SpringerLink
Log in

The role of the inflammasome in cardiovascular diseases

  • Review
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Inflammasome is a very important signaling platform sensing a variety of triggers of the innate immune system. Inflammasome promotes the production of important pro-inflammatory cytokines such as IL-1β and IL-18. Tight control of inflammasome activity is, therefore, essential and occurs at multiple levels. The activation of inflammasome pathways is linked to the pathogenesis of various prevalent disorders including cardiovascular disease such as atherosclerosis, ischemic injury, cardiomyopathy, and Kawasaki disease. The study of the inflammasome in the cardiovascular system has led to the identification of important triggers and endogenous modulators, and to the exploration of new treatment strategies based on the inhibition of inflammasome activation or its end products, i.e., IL-1β and IL-18. In summary, the discovery of the inflammasome has greatly advanced our understanding of how the innate immune system interferes with cardiovascular disease development and progression, and targeting inflammasome provides new avenues for the treatment and management of cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11:897–904

    PubMed Central  PubMed  CAS  Google Scholar 

  2. Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC et al (2013) Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 19:1132–1140

    PubMed  CAS  Google Scholar 

  3. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC et al (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:674–678

    PubMed  CAS  Google Scholar 

  4. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241

    PubMed  CAS  Google Scholar 

  5. Roberts RL, Topless RK, Phipps-Green AJ, Gearry RB, Barclay ML, Merriman TR (2010) Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immunol 11:351–356

    CAS  Google Scholar 

  6. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13:343–351

    PubMed  CAS  Google Scholar 

  7. Sun Y, Zhang M, Chen CC, Gillilland M 3rd, Sun X, El-Zaatari M, Huffnagle GB, Young VB, Zhang J, Hong SC et al (2013) Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 144:1478–1487, 1487 e1471-1478

    PubMed  CAS  Google Scholar 

  8. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357–1361

    PubMed Central  PubMed  CAS  Google Scholar 

  9. Davis BK, Wen H, Ting JP (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29:707–735

    PubMed  CAS  Google Scholar 

  10. Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES (2002) The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 277:21119–21122

    PubMed  CAS  Google Scholar 

  11. Bae JY, Park HH (2011) Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J Biol Chem 286:39528–39536

    PubMed Central  PubMed  CAS  Google Scholar 

  12. Hiller S, Kohl A, Fiorito F, Herrmann T, Wider G, Tschopp J, Grutter MG, Wuthrich K (2003) NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 11:1199–1205

    PubMed  CAS  Google Scholar 

  13. Gross O, Thomas CJ, Guarda G, Tschopp J (2011) The inflammasome: an integrated view. Immunol Rev 243:136–151

    PubMed  CAS  Google Scholar 

  14. Kersse K, Bertrand MJ, Lamkanfi M, Vandenabeele P (2011) NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev 22:257–276

    PubMed  CAS  Google Scholar 

  15. Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210–215

    PubMed  CAS  Google Scholar 

  16. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857–865

    PubMed Central  PubMed  CAS  Google Scholar 

  17. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856

    PubMed Central  PubMed  CAS  Google Scholar 

  18. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G (2013) K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38:1142–1153

    PubMed  CAS  Google Scholar 

  19. Lukens JR, Gross JM, Kanneganti TD (2012) IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol 3:315

    PubMed Central  PubMed  Google Scholar 

  20. Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40:599–606

    PubMed  CAS  Google Scholar 

  21. Sheikh S, Rahman M, Gale Z, Luu NT, Stone PC, Matharu NM, Rainger GE, Nash GB (2005) Differing mechanisms of leukocyte recruitment and sensitivity to conditioning by shear stress for endothelial cells treated with tumour necrosis factor-alpha or interleukin-1beta. Br J Pharmacol 145:1052–1061

    PubMed Central  PubMed  CAS  Google Scholar 

  22. Santarlasci V, Cosmi L, Maggi L, Liotta F, Annunziato F (2013) IL-1 and T Helper Immune Responses. Front Immunol 4:182

    PubMed Central  PubMed  Google Scholar 

  23. Ben-Sasson SZ, Caucheteux S, Crank M, Hu-Li J, Paul WE (2011) IL-1 acts on T cells to enhance the magnitude of in vivo immune responses. Cytokine 56:122–125

    PubMed Central  PubMed  CAS  Google Scholar 

  24. Warner SJ, Auger KR, Libby P (1987) Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med 165:1316–1331

    PubMed  CAS  Google Scholar 

  25. Libby P, Warner SJ, Friedman GB (1988) Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 81:487–498

    PubMed Central  PubMed  CAS  Google Scholar 

  26. Akira S (2000) The role of IL-18 in innate immunity. Curr Opin Immunol 12:59–63

    PubMed  CAS  Google Scholar 

  27. Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73:213–224

    PubMed  CAS  Google Scholar 

  28. Srivastava S, Salim N, Robertson MJ (2010) Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem 17:3353–3357

    PubMed  CAS  Google Scholar 

  29. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474

    PubMed  CAS  Google Scholar 

  30. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53–72

    PubMed  CAS  Google Scholar 

  31. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene I (2002) Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106:24–30

    PubMed  CAS  Google Scholar 

  32. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A (2002) Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 88:467–469

    PubMed Central  PubMed  CAS  Google Scholar 

  33. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, Seidler T, Hasenfuss G, Chvatchko Y, Shah AM et al (2004) Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 18:1752–1754

    PubMed  CAS  Google Scholar 

  34. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C (2005) Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes 54:2932–2938

    PubMed  CAS  Google Scholar 

  35. Kone-Paut I, Piram M (2012) Targeting interleukin-1beta in CAPS (cryopyrin-associated periodic) syndromes: what did we learn? Autoimmun Rev 12:77–80

    PubMed  CAS  Google Scholar 

  36. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652

    PubMed Central  PubMed  CAS  Google Scholar 

  37. Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7:99–109

    PubMed Central  PubMed  CAS  Google Scholar 

  38. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S et al (2011) Non-canonical inflammasome activation targets caspase-11. Nature 479:117–121

    PubMed  CAS  Google Scholar 

  39. Broz P, Ruby T, Belhocine K, Bouley DM, Kayagaki N, Dixit VM, Monack DM (2012) Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490:288–291

    PubMed Central  PubMed  CAS  Google Scholar 

  40. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszynski A et al (2013) Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341:1246–1249

    PubMed  CAS  Google Scholar 

  41. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, Vajjhala PR, Roberts TL, Schroder K, Vince JE, Hill JM et al (2013) AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 20:1149–1160

    PubMed  CAS  Google Scholar 

  42. Pierini R, Juruj C, Perret M, Jones CL, Mangeot P, Weiss DS, Henry T (2012) AIM2/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell Death Differ 19:1709–1721

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411

    PubMed  CAS  Google Scholar 

  44. Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M, Louie S, Kayagaki N, Liu J, Komuves L et al (2012) Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 490:539–542

    PubMed  CAS  Google Scholar 

  45. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH (2012) Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 13:255–263

    PubMed  CAS  Google Scholar 

  46. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES (2012) Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 287:36617–36622

    PubMed Central  PubMed  CAS  Google Scholar 

  47. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sassetti CM (2013) Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 14:52–60

    PubMed Central  PubMed  CAS  Google Scholar 

  48. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S (2013) Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 14:454–460

    PubMed  CAS  Google Scholar 

  49. Qiao Y, Wang P, Qi J, Zhang L, Gao C (2012) TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett 586:1022–1026

    PubMed  CAS  Google Scholar 

  50. Jefferies C, Wynne C, Higgs R (2011) Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease? Nat Rev Immunol 11:617–625

    PubMed  CAS  Google Scholar 

  51. Le HT, Harton JA (2013) Pyrin- and CARD-only Proteins as Regulators of NLR Functions. Front Immunol 4:275

    PubMed Central  PubMed  Google Scholar 

  52. Deretic V, Saitoh T, Akira S (2013) Autophagy in infection, inflammation and immunity. Nat Rev Immunol 13:722–737

    PubMed  CAS  Google Scholar 

  53. Harris J (2013) Autophagy and IL-1 family cytokines. Front Immunol 4:83

    PubMed Central  PubMed  Google Scholar 

  54. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223

    PubMed  Google Scholar 

  55. Libby P, Lichtman AH, Hansson GK (2013) Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38:1092–1104

    PubMed  CAS  Google Scholar 

  56. Yin Y, Pastrana JL, Li X, Huang X, Mallilankaraman K, Choi ET, Madesh M, Wang H, Yang XF (2013) Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) 18:638–649

    CAS  Google Scholar 

  57. Reiner AP, Beleza S, Franceschini N, Auer PL, Robinson JG, Kooperberg C, Peters U, Tang H (2012) Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. Am J Hum Genet 91:502–512

    PubMed Central  PubMed  CAS  Google Scholar 

  58. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P et al (2011) Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123:731–738

    PubMed Central  PubMed  CAS  Google Scholar 

  59. Yin Y, Yan Y, Jiang X, Mai J, Chen NC, Wang H, Yang XF (2009) Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol 22:311–322

    PubMed Central  PubMed  CAS  Google Scholar 

  60. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT et al (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14:812–820

    PubMed Central  PubMed  CAS  Google Scholar 

  61. Kokjohn TA, Van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI et al (2011) Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 1812:1508–1514

    PubMed Central  PubMed  CAS  Google Scholar 

  62. Scull CM, Tabas I (2011) Mechanisms of ER stress-induced apoptosis in atherosclerosis. Arterioscler Thromb Vasc Biol 31:2792–2797

    PubMed Central  PubMed  CAS  Google Scholar 

  63. Menu P, Mayor A, Zhou R, Tardivel A, Ichijo H, Mori K, Tschopp J (2012) ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis 3:e261

    PubMed Central  PubMed  CAS  Google Scholar 

  64. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11:136–140

    PubMed  CAS  Google Scholar 

  65. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J et al (2010) Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 59:1424–1434

    PubMed Central  PubMed  CAS  Google Scholar 

  66. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED et al (2008) Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49:2101–2112

    PubMed Central  PubMed  CAS  Google Scholar 

  67. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179–188

    PubMed Central  PubMed  CAS  Google Scholar 

  68. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA et al (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11:155–161

    PubMed Central  PubMed  CAS  Google Scholar 

  69. Neogi T, Ellison RC, Hunt S, Terkeltaub R, Felson DT, Zhang Y (2009) Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol 36:378–384

    PubMed Central  PubMed  Google Scholar 

  70. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, Group MR (2008) Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 168:1104–1110

    Google Scholar 

  71. Bostanci N, Emingil G, Saygan B, Turkoglu O, Atilla G, Curtis MA, Belibasakis GN (2009) Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin Exp Immunol 157:415–422

    PubMed Central  PubMed  CAS  Google Scholar 

  72. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Sacco RL, Papapanou PN (2005) Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 111:576–582

    PubMed Central  PubMed  Google Scholar 

  73. Spirig R, Tsui J, Shaw S (2012) The emerging role of TLR and innate immunity in cardiovascular disease. Cardiol Res Pract 2012:181394

    PubMed Central  PubMed  Google Scholar 

  74. Erridge C (2008) The roles of pathogen-associated molecular patterns in atherosclerosis. Trends Cardiovasc Med 18:52–56

    PubMed  CAS  Google Scholar 

  75. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101:10679–10684

    PubMed Central  PubMed  CAS  Google Scholar 

  76. Mullick AE, Tobias PS, Curtiss LK (2005) Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115:3149–3156

    PubMed Central  PubMed  CAS  Google Scholar 

  77. Ordovas-Montanes JM, Ordovas JM (2012) Cholesterol, inflammasomes, and atherogenesis. Curr Cardiovasc Risk Rep 6:45–52

    PubMed Central  PubMed  Google Scholar 

  78. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL (2003) Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 278:1561–1568

    PubMed  CAS  Google Scholar 

  79. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:C917–C924

    PubMed  CAS  Google Scholar 

  80. Yu L, Wang L, Chen S (2010) Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 14:2592–2603

    PubMed  CAS  Google Scholar 

  81. Lin L (2006) RAGE on the Toll road? Cell Mol Immunol 3:351–358

    PubMed  CAS  Google Scholar 

  82. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM (1996) Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 16:1000–1006

    PubMed  CAS  Google Scholar 

  83. Moyer CF, Sajuthi D, Tulli H, Williams JK (1991) Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 138:951–960

    PubMed Central  PubMed  CAS  Google Scholar 

  84. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M (2003) Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 23:656–660

    PubMed  CAS  Google Scholar 

  85. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, James RW, Mach F, Gabay C (2005) Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovascular research 66:583–593

    PubMed  CAS  Google Scholar 

  86. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, Ohsuzu F (2004) Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24:1068–1073

    PubMed  CAS  Google Scholar 

  87. Bouki KP, Katsafados MG, Chatzopoulos DN, Psychari SN, Toutouzas KP, Charalampopoulos AF, Sakkali EN, Koudouri AA, Liakos GK, Apostolou TS (2012) Inflammatory markers and plaque morphology: an optical coherence tomography study. Int J Cardiol 154:287–292

    PubMed  Google Scholar 

  88. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A (2001) Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104:1598–1603

    PubMed  CAS  Google Scholar 

  89. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A (2001) Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89:E41–E45

    PubMed  CAS  Google Scholar 

  90. Thompson SR, Novick D, Stock CJ, Sanders J, Brull D, Cooper J, Woo P, Miller G, Rubinstein M, Humphries SE (2007) Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arterioscler Thromb Vasc Biol 27:2743–2749

    PubMed  CAS  Google Scholar 

  91. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L, Group PS (2003) Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108:2453–2459

    Google Scholar 

  92. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O et al (2005) Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112:643–650

    PubMed  CAS  Google Scholar 

  93. Barbaux S, Poirier O, Godefroy T, Kleinert H, Blankenberg S, Cambien F, Tiret L (2007) Differential haplotypic expression of the interleukin-18 gene. Eur J Hum Genet : EJHG 15:856–863

    PubMed  CAS  Google Scholar 

  94. Grisoni ML, Proust C, Alanne M, DeSuremain M, Salomaa V, Kuulasmaa K, Cambien F, Nicaud V, Stegmayr B, Virtamo J et al (2008) Haplotypic analysis of tag SNPs of the interleukin-18 gene in relation to cardiovascular disease events: the MORGAM Project. Eur J Hum Genet : EJHG 16:1512–1520

    PubMed  CAS  Google Scholar 

  95. Whitman SC, Ravisankar P, Daugherty A (2002) Interleukin-18 enhances atherosclerosis in apolipoprotein E(−/−) mice through release of interferon-gamma. Circ Res 90:E34–E38

    PubMed  CAS  Google Scholar 

  96. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R (2000) Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 157:1259–1268

    PubMed Central  PubMed  CAS  Google Scholar 

  97. Blankenberg S, Godefroy T, Poirier O, Rupprecht HJ, Barbaux S, Bickel C, Nicaud V, Schnabel R, Kee F, Morrison C et al (2006) Haplotypes of the caspase-1 gene, plasma caspase-1 levels, and cardiovascular risk. Circ Res 99:102–108

    PubMed  CAS  Google Scholar 

  98. Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, Karasawa T, Hida S, Sagara J, Taniguchi S, Takahashi M (2012) Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun 425:162–168

    PubMed  CAS  Google Scholar 

  99. Gage J, Hasu M, Thabet M, Whitman SC (2012) Caspase-1 deficiency decreases atherosclerosis in apolipoprotein E-null mice. Can J Cardiol 28:222–229

    PubMed  CAS  Google Scholar 

  100. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, Mazzolai L, Tschopp J (2011) Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis 2:e137

    PubMed Central  PubMed  CAS  Google Scholar 

  101. Grainger DJ, Reckless J, McKilligin E (2004) Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 173:6366–6375

    PubMed  CAS  Google Scholar 

  102. Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S, White M, Voronov E, Dinarello CA, Apte RN et al (2011) Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1alpha. Biochem Biophys Res Commun 405:197–203

    PubMed  CAS  Google Scholar 

  103. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J (2012) Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36:388–400

    PubMed  CAS  Google Scholar 

  104. Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M (2007) The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 282:36321–36329

    PubMed  CAS  Google Scholar 

  105. Staal J, Bekaert T, Beyaert R (2011) Regulation of NF-kappaB signaling by caspases and MALT1 paracaspase. Cell Res 21:40–54

    PubMed Central  PubMed  CAS  Google Scholar 

  106. Keller M, Ruegg A, Werner S, Beer HD (2008) Active caspase-1 is a regulator of unconventional protein secretion. Cell 132:818–831

    PubMed  CAS  Google Scholar 

  107. Freigang S, Ampenberger F, Weiss A, Kanneganti TD, Iwakura Y, Hersberger M, Kopf M (2013) Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat Immunol 14:1045–1053

    PubMed  CAS  Google Scholar 

  108. Takahashi M (2011) Role of the inflammasome in myocardial infarction. Trends Cardiovasc Med 21:37–41

    PubMed  CAS  Google Scholar 

  109. Zhu P, Duan L, Chen J, Xiong A, Xu Q, Zhang H, Zheng F, Tan Z, Gong F, Fang M (2011) Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 22:853–864

    PubMed  CAS  Google Scholar 

  110. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, Hall WF, Correia Jda S, Ulevitch RJ, Hoffman HM, McKay DB (2010) An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 185:6277–6285

    PubMed Central  PubMed  CAS  Google Scholar 

  111. Li H, Ambade A, Re F (2009) Cutting edge: necrosis activates the NLRP3 inflammasome. J Immunol 183:1528–1532

    PubMed  CAS  Google Scholar 

  112. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC et al (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 106:20388–20393

    PubMed Central  PubMed  CAS  Google Scholar 

  113. Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161

    PubMed  CAS  Google Scholar 

  114. Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW, Dietrich WD (2009) Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab 29:534–544

    PubMed  CAS  Google Scholar 

  115. Liu HD, Li W, Chen ZR, Hu YC, Zhang DD, Shen W, Zhou ML, Zhu L, Hang CH (2013) Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem Res 38:2072–2083

    PubMed  CAS  Google Scholar 

  116. Liu SB, Mi WL, Wang YQ (2013) Research progress on the NLRP3 inflammasome and its role in the central nervous system. Neurosci Bull 29(6):779–787

    PubMed  CAS  Google Scholar 

  117. Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J et al (2013) Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 4:e790

    PubMed  CAS  Google Scholar 

  118. Yang-Wei Fann D, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J et al (2013) Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 4:e790

    PubMed Central  PubMed  Google Scholar 

  119. Hara H, Fink K, Endres M, Friedlander RM, Gagliardini V, Yuan J, Moskowitz MA (1997) Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab 17:370–375

    PubMed  CAS  Google Scholar 

  120. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ (2001) Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 21:5528–5534

    PubMed  CAS  Google Scholar 

  121. Fann DY, Lee SY, Manzanero S, Chunduri P, Sobey CG, Arumugam TV (2013) Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res Rev 12:941–966

    PubMed  CAS  Google Scholar 

  122. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629–640

    PubMed  CAS  Google Scholar 

  123. Gu L, Xiong X, Zhang H, Xu B, Steinberg GK, Zhao H (2012) Distinctive effects of T cell subsets in neuronal injury induced by cocultured splenocytes in vitro and by in vivo stroke in mice. Stroke: J Cereb Circ 43:1941–1946

    CAS  Google Scholar 

  124. Melani A, Turchi D, Vannucchi MG, Cipriani S, Gianfriddo M, Pedata F (2005) ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int 47:442–448

    PubMed  CAS  Google Scholar 

  125. Deroide N, Li X, Lerouet D, Van Vre E, Baker L, Harrison J, Poittevin M, Masters L, Nih L, Margaill I et al (2013) MFGE8 inhibits inflammasome-induced IL-1beta production and limits postischemic cerebral injury. J Clin Invest 123:1176–1181

    PubMed Central  PubMed  CAS  Google Scholar 

  126. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA (2001) Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 98:2871–2876

    PubMed Central  PubMed  CAS  Google Scholar 

  127. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J et al (2011) Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123:594–604

    PubMed  CAS  Google Scholar 

  128. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A (2011) The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108:19725–19730

    PubMed Central  PubMed  CAS  Google Scholar 

  129. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GG, Houser JE, Qureshi IZ, Ownby ED et al (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117:2670–2683

    PubMed  CAS  Google Scholar 

  130. Wang M, Tan J, Wang Y, Meldrum KK, Dinarello CA, Meldrum DR (2009) IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Proc Natl Acad Sci USA 106:17499–17504

    PubMed Central  PubMed  CAS  Google Scholar 

  131. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR Jr, Macdonald JA, Lees-Miller JP, Roach D et al (2013) The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol 98:462–472

    PubMed  CAS  Google Scholar 

  132. Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G, Merlo M, Mezzaroma E, De-Giorgio F, Silvestri F et al (2014) Formation of the inflammasome in acute myocarditis. Int J Cardiol 171:e119–e121

    PubMed  Google Scholar 

  133. Syed FM, Hahn HS, Odley A, Guo Y, Vallejo JG, Lynch RA, Mann DL, Bolli R, Dorn GW 2nd (2005) Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res 96:1103–1109

    PubMed  CAS  Google Scholar 

  134. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, Fishbein MC, Lehman TJ, Arditi M (2012) Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 125:1542–1550

    PubMed Central  PubMed  CAS  Google Scholar 

  135. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP et al (2010) Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem 285:9792–9802

    PubMed Central  PubMed  CAS  Google Scholar 

  136. Keystone EC, Wang MM, Layton M, Hollis S, McInnes IB, Team DCS (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630–1635

    PubMed  CAS  Google Scholar 

  137. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V et al (2008) NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke: J Cereb Circ 39:1751–1758

    CAS  Google Scholar 

  138. Edaravone Acute Infarction Study G (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222–229

    Google Scholar 

  139. Callus BA, Vaux DL (2007) Caspase inhibitors: viral, cellular and chemical. Cell Death Differ 14:73–78

    PubMed  CAS  Google Scholar 

  140. Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ (2007) A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 53:638–642

    PubMed  CAS  Google Scholar 

  141. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M (2000) Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 20:4398–4404

    PubMed  CAS  Google Scholar 

  142. Mitroulis I, Skendros P, Ritis K (2010) Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 21:157–163

    PubMed  CAS  Google Scholar 

  143. Banwell V, Sena ES, Macleod MR (2009) Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 18:269–276

    PubMed  Google Scholar 

  144. Johnston WF, Salmon M, Su G, Lu G, Stone ML, Zhao Y, Owens GK, Upchurch GR Jr, Ailawadi G (2013) Genetic and pharmacologic disruption of interleukin-1beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 33:294–304

    PubMed Central  PubMed  CAS  Google Scholar 

  145. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH et al (2013) Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 111:1394–1400

    PubMed Central  PubMed  CAS  Google Scholar 

  146. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A et al (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105(1371–1377):e1371

    Google Scholar 

  147. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE (2008) Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 9:8

    PubMed Central  PubMed  Google Scholar 

  148. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrrell PJ, Acute Stroke I (2005) A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 76:1366–1372

    PubMed Central  PubMed  CAS  Google Scholar 

  149. Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597–605

    PubMed  CAS  Google Scholar 

  150. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, Group CPI (2012) Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126:2739–2748

    PubMed  CAS  Google Scholar 

  151. Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, Chandrasekar B (2009) Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury. J Biol Chem 284:7853–7865

    PubMed Central  PubMed  CAS  Google Scholar 

  152. Takeuchi D, Yoshidome H, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M (2004) Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 39:699–710

    PubMed  CAS  Google Scholar 

  153. Tak PP, Bacchi M, Bertolino M (2006) Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet 31:109–116

    PubMed  CAS  Google Scholar 

  154. Keller M, Sollberger G, Beer HD (2009) Thalidomide inhibits activation of caspase-1. J Immunol 183:5593–5599

    PubMed  CAS  Google Scholar 

  155. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM (2009) Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187:61–70

    PubMed Central  PubMed  CAS  Google Scholar 

  156. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507–3512

    PubMed Central  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work is supported by an ERC Starting Grant to Ziad Mallat.

Disclosure

The authors declare that they have no conflict of interests.

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, CB2 2QQ, UK

    Xuan Li, Nicolas Deroide & Ziad Mallat

  2. Institut National de la Santé et de la Recherche Médicale, Paris Cardiovascular Research Center, Unit 970, 75015, Paris, France

    Ziad Mallat

Authors
  1. Xuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Deroide
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziad Mallat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ziad Mallat.

Additional information

X. Li and N. Deroide contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, X., Deroide, N. & Mallat, Z. The role of the inflammasome in cardiovascular diseases. J Mol Med 92, 307–319 (2014). https://doi.org/10.1007/s00109-014-1144-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-014-1144-3

Keywords

Search

Navigation